Phase 3 Endometrial Cancer Trial, Recruiting NCT07298642 Sponsor: National Taiwan University Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT07298642
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with cervical cancer (confirmed by a tissue sample/biopsy) that is at stage IIIC or higher.
  • You are between 20 and 85 years old.
  • You are fairly active and able to carry out daily activities with little to no limitation (confirm with trial site).
  • Your doctor has determined that you are suitable for a type of radiation treatment that covers a wider area of the body, called extended-field radiotherapy.
  • You may have received up to 6 weeks or 2 rounds of initial chemotherapy using the drugs paclitaxel and carboplatin before joining.
  • During radiation treatment, you may receive either radiation alone, or one chemotherapy drug at a time (weekly cisplatin or carboplatin), but no other cancer-fighting drugs at the same time.
  • You may receive additional chemotherapy or immunotherapy after radiation treatment is completed.

Who may not be able to join:

  • You have previously had radiation therapy to your pelvis or abdomen.
  • Your cancer has spread to distant parts of the body, or you have had another active cancer in the past 5 years (skin cancers that are not melanoma are generally excepted — confirm with trial site).
  • You have serious ongoing health conditions, such as uncontrolled diabetes, heart disease, or autoimmune disorders, that could interfere with treatment or taking part in the study.
  • You are currently pregnant or breastfeeding.
  • You have psychiatric or personal/social circumstances that might make it difficult to follow the study's requirements or attend follow-up visits.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886-2-23123456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
1 May 2030

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Lymphocyte Counts; Immune Cell Subsets

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov